NEXGEL INC (NASDAQ:NXGL) Reports Mixed Q3 2025 Results with Revenue Miss and Narrower-Than-Expected Loss

NEXGEL INC (NASDAQ:NXGL) reported its third quarter 2025 financial results, revealing a mixed performance against analyst expectations. The hydrogel manufacturer posted revenue and earnings figures that diverged from projections, prompting varied market reactions in after-hours and recent trading sessions.

Quarterly Financial Performance

The company's Q3 2025 results showed notable deviations from analyst consensus estimates:

• Revenue: $2.93 million reported versus $3.23 million estimated
• EPS (Non-GAAP): -$0.08 reported versus -$0.0816 estimated

While the earnings per share loss was slightly narrower than analysts had anticipated, the company fell short on the top-line revenue figure. This revenue miss of approximately 9.2% suggests that sales performance during the quarter did not meet market expectations, despite the marginally better-than-expected bottom-line result.

Market Reaction and Price Action

The market's immediate response to the earnings release appears measured, with after-market trading showing a decline of approximately 1.75%. This reaction reflects investor sentiment weighing the mixed earnings picture against broader company performance. Recent trading patterns provide additional context for understanding the stock's trajectory:

• Weekly Performance: +3.63%
• Bi-weekly Performance: -10.94%
• Monthly Performance: -11.63%

The positive weekly performance leading into the earnings announcement may have reflected investor optimism, while the broader monthly decline indicates persistent challenges the company has faced in recent weeks.

Business Outlook and Analyst Projections

Looking ahead, analyst estimates provide a framework for evaluating NEXGEL's future performance trajectory. For the upcoming fourth quarter of 2025, the consensus stands at:

• Estimated Revenue: $3.71 million
• Estimated EPS: -$0.0306

Full-year 2025 projections indicate:

• Estimated Revenue: $12.74 million
• Estimated EPS: -$0.2856

These forward-looking estimates will serve as important benchmarks as the company progresses through the remainder of the fiscal year and investors assess its ability to meet or exceed these projections.

Corporate Developments and Strategic Positioning

According to the earnings release, NEXGEL continues to position itself as a provider of ultra-gentle, high-water-content hydrogel products serving healthcare, beauty, and over-the-counter markets. The company operates through two primary segments: its core NexGel manufacturing business based in Pennsylvania and its CGN joint venture focused on converting and packaging operations in Texas. This dual-segment approach allows the company to leverage proprietary manufacturing technologies while maintaining control over its packaging processes through the joint venture structure.

For detailed historical earnings data and comprehensive analyst estimates, readers can access additional information through the NEXGEL earnings and estimates page.

Disclaimer: This article presents factual information based on publicly available data and should not be construed as investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions.